Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2025 07:30 ET | Source: MicrobiotiX

MicrobiotiX and West Africa Centre for Innovative Research and Care in Ghana Sign MoU to Advance Clinical Development of Bacteriophage Therapeutics and Combat AMR·MDR in Africa

MicrobiotiX and KATH sign MoU to advance clinical bacteriophage therapies against AMR·MDR and expand treatment options for patients in Africa.
October 27, 2025 07:30 ET | Source: MicrobiotiX

MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101

MicrobiotiX gains IND approval to initiate clinical trials for its pneumonia therapy designed to combat antibiotic-resistant superbugs.
September 04, 2025 11:00 ET | Source: Research and Markets

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer

Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Australia Acute Respiratory Distress Syndrome Market Analysis 2025" report has been added to ResearchAndMarkets.com's offering.The Australia Acute...
September 04, 2025 10:46 ET | Source: Research and Markets

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ...
July 02, 2025 05:07 ET | Source: Research and Markets

United States Virology, Bacteriology, Parasitology and Mycology Market Forecasts and Supplier Shares: Supplier Shares and Future Forecasts Revealed for Major Infectious Disease Tests

Dublin, July 02, 2025 (GLOBE NEWSWIRE) -- The "2025 U.S. Virology, Bacteriology, Parasitology and Mycology Market Forecasts and Supplier Shares: Shares, Volume and Sales Segment Forecasts for 100...
April 03, 2025 04:02 ET | Source: Research and Markets

Community Acquired Pneumonia Research Report 2025: Market Expected to Reach USD 3.09 Billion by 2032 - Explore the Impact of Combination Therapies and Diagnostic Advances

Dublin, April 03, 2025 (GLOBE NEWSWIRE) -- The "Community Acquired Pneumonia Market" report has been added to ResearchAndMarkets.com's offering. The global market for community-acquired pneumonia...
March 19, 2025 12:19 ET | Source: Research and Markets

Acute Respiratory Distress Syndrome Market Forecast Report and Company Analysis 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun,Teva

Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ...
October 29, 2024 12:30 ET | Source: Custom Market Insights

[Latest] Global Acute Respiratory Infection Market Size/Share Worth USD 20,796.6 Billion by 2033 at a 1.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acute Respiratory Infection Market Size, Trends and Insights By Drug Type...
October 22, 2024 00:30 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
September 12, 2024 16:56 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC

NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...